Published in J Clin Psychiatry on March 01, 2002
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care. Psychol Sci Public Interest (2008) 1.34
Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res (2009) 1.07
Comparison of the effectiveness of trauma-focused cognitive behavioral therapy and paroxetine treatment in PTSD patients: design of a randomized controlled trial. BMC Psychiatry (2012) 0.89
Functional impairment in adults with past posttraumatic stress disorder: findings from primary care. Depress Anxiety (2011) 0.86
Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials. Curr Opin Investig Drugs (2009) 0.84
Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury. J Addict Med (2009) 0.80
Efficacy of chronic antidepressant treatments in a new model of extreme anxiety in rats. Depress Res Treat (2011) 0.80
Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents. P T (2012) 0.79
Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention. Psychiatry (Edgmont) (2005) 0.79
Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). Behav Sci (Basel) (2014) 0.78
Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl) (2005) 0.77
Pharmacotherapy of PTSD: Current Status and Controversies. Psychiatr Ann (2009) 0.76
Decreased suicidal ideation in depressed patients with or without comorbid posttraumatic stress disorder treated with selective serotonin reuptake inhibitors: an open study. Psychiatry Res (2012) 0.75
Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center. J Clin Med (2016) 0.75
Better Sleep in a Strange Bed? Sleep Quality in South African Women with Posttraumatic Stress Disorder. Front Psychol (2017) 0.75
Pharmacotherapy of post-traumatic stress disorder: going beyond the guidelines. BJPsych Open (2016) 0.75
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry (2002) 2.20
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res (2005) 1.95
A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry (2002) 1.89
Pharmacotherapy for stress urinary incontinence : present and future options. Drugs (2004) 1.48
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin (2007) 1.09
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol (2011) 1.05
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin (2007) 1.04
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology (2007) 1.04
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med (2007) 0.98
Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull (2009) 0.95
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol (2012) 0.92
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol (2005) 0.91
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety (2007) 0.89
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin (2008) 0.87
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res (2005) 0.86
Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull (2007) 0.85
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry (2006) 0.85
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol (2014) 0.84
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol (2004) 0.82
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol (2014) 0.81
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol (2007) 0.80
Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Clin J Pain (2009) 0.79
Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications (2008) 0.78
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry (2002) 0.78
Evaluation of sentinel node biopsy in locally advanced breast cancer patients who become clinically node-negative after neoadjuvant chemotherapy: a preliminary study. Int J Breast Cancer (2011) 0.77
The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin (2008) 0.77
Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine. J Clin Psychopharmacol (2004) 0.77
Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochim Biophys Sin (Shanghai) (2009) 0.76
Addressing methodological issues in studying antidepressant onset efficacy using prespecified sensitivity analyses. Psychopharmacol Bull (2008) 0.75
Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. Clin Pharmacokinet (2014) 0.75
Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol (2002) 0.75
Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol (2006) 0.75
Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol (2003) 0.75
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol (2015) 0.75